Sector News

GSK announces investment in UK manufacturing network

July 28, 2016
Life sciences

GSK today announced £275 million of new investments at three of its manufacturing sites in the UK to boost production and support delivery of its latest innovative respiratory and large molecule biological medicines. The vast majority of these products will be for export to global markets.

GSK has a significant manufacturing presence in the UK, with nine sites employing approximately 6,000 people. The company views the UK as an attractive location for investment in advanced manufacturing due to a number of factors including the skilled workforce, technological and scientific capabilities & infrastructure and a competitive corporate tax system. This includes the Patent Box, which encourages investment in R&D and related manufacturing in the UK by delivering a lower rate of corporation tax on profits generated from UK-owned intellectual property.

Andrew Witty, CEO, GSK said, ‘Today’s announcement reflects further investment to support our pharmaceutical pipeline and meet growing demand for our innovative portfolio of newly launched products. It is testament to our skilled UK workforce and the country’s leading position in life sciences that we are making these investments in advanced manufacturing here. From their manufacture in the UK, many of these medicines will be sent to patients around the world.’

The investment announced today is split across three UK sites:

  • Barnard Castle in County Durham is one of GSK’s biggest secondary manufacturing sites, employing 1,100 people. The site supplies nearly half a million packs of products per day to 140 global markets. The investment announced today of £92 million will fund the construction of an aseptic sterile facility supporting the manufacture of existing and new biopharmaceutical assets in our pipeline.
  • Montrose in Angus in Scotland manufactures active ingredients for respiratory, HIV and vaccine products and employs over 450 staff. This investment of approximately £110 million will provide a new, state-of-the-art facility for the manufacture of respiratory active ingredients.
  • Ware in Hertfordshire, employs 1200 staff, manufacturing innovative respiratory products. Today’s investment of £74 million will support further expansion of the company’s new Ellipta respiratory inhaler through additional manufacturing capacity at the site.

In addition to jobs associated with the construction of the new facilities, today’s announcement will support current employment at these three sites and is expected to lead to the creation of new employment opportunities.

Source: GSK

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach